(Q53327087)

13 May 2018

title

Depression in schizophrenia: recognition and management in the USA. (English)

1 reference

13 May 2018

0 references

S G Siris

1

1 reference

13 May 2018

D Addington

2

1 reference

13 May 2018

J M Azorin

3

1 reference

13 May 2018

I R Falloon

4

1 reference

13 May 2018

J Gerlach

5

1 reference

13 May 2018

S R Hirsch

6

1 reference

13 May 2018

language of work or name

English

0 references

publication date

1 March 2001

1 reference

13 May 2018

published in

Schizophrenia Research

1 reference

13 May 2018

volume

47

1 reference

13 May 2018

issue

2-3

1 reference

13 May 2018

page(s)

185-197

1 reference

13 May 2018

A depression rating scale for schizophrenics

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Specificity of the Calgary Depression Scale for schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Schizophrenia: a life-shortening disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Schizophrenics kill themselves too: a review of risk factors for suicide

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Imipramine-flupenthixol decanoate interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Depression and Social Adjustment Among Chronic Schizophrenic Outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

A Survey of Practising Psychiatrists' Views on the Treatment of Agoraphobia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Interaction between antidepressants and perphenazine in psychiatric inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Interaction of Chlorpromazine and Nortriptyline in Patients with Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Postpsychotic depression in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Antidepressant Usage in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Depression in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Suicidal behavior in chronic schizophrenic patients: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Diagnosis of secondary depression in schizophrenia: implications for DSM-IV.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Use of Antidepressant Drugs in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Adjunctive imipramine for a broader group of post-psychotic depressions in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900135-3

7 January 2021

10.1016/S0920-9964(00)00135-3

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018